Humana, Eli Lilly And A Major Mining Stock On CNBC’s ‘Final Trades’

On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Freeport-McMoRan Inc. (NYSE: FCX), adding that she likes the stock

On CNBC’s “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management named Freeport-McMoRan Inc. (NYSE:FCX), adding that she likes the stock here in the mid-30s.

Freeport-McMoRan reported third-quarter revenue growth of 16.4% year-over-year to $5.82 billion, topping the consensus of $5.41 billion. Adjusted EPS of 39 cents exceeded the consensus estimate of 34 cents.

Stephen Weiss of Short Hills Capital Partners said Humana Inc. (NYSE:HUM) was up around 2% on Monday, but it’s “down quite a bit.”

Humana reported third-quarter adjusted EPS of $7.78 compared to $7.31 a year ago, beating the consensus of $7.16.

Don’t forget to check out our premarket coverage here

Joseph Terranova of Virtus Investment Partners named Eli Lilly and Company (NYSE:LLY) as his final trade.

Eli Lilly reported better-than-expected financial results for the third quarter.

Price Action: Freeport-McMoRan shares gained 0.6% to close at $35.37, while Humana shares gained 2.2% to settle at $487.31on Monday. Eli Lilly gained 4.8% to close at $595.19 during Monday’s session.

Check This Out: Uber, D.R. Horton And 3 Stocks To Watch Heading Into Tuesday

Photo: Shutterstock

Total
0
Shares
Related Posts
Read More

Biora Therapeutics Provides Guidance On Anticipated Milestones During 2024; Says We Begin 2024 In The Clinic With Our Phase 1 Study For BT-600, Which Will Be A Major De-Risking Step In The Development Of Our NaviCap Platform

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today provided guidance on anticipated milestones during 2024. "In 2023, we completed the transformation of

BIOR